NASDAQ: PTCT · Life Sciences · 10 alerts · CIK 1070081
Share price
$60.97Close, Nov 16
Market cap
$5.09B
Shares outstanding
83.54MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All PTC Therapeutics, Inc. filings on SEC EDGAR ↗
PTC Therapeutics announced that its Board of Directors has authorized a share repurchase program to buy back up to $500 million of its common stock. The repurchases will be conducted at management's discretion through open-market or privately negotiated transactions based on market conditions.
For the nine months ended September 30, 2026, PTC Therapeutics reported total revenues of $990.9 million and net income of $29.0 million, a significant decrease from the $817.6 million net income in the prior year period which was bolstered by high collaboration revenue. The company's balance sheet remains strong with $2.1 billion in cash, cash equivalents, and marketable securities, though it maintains a total stockholders' deficit of $191.2 million.
PTC Therapeutics reported record third-quarter 2026 financial results, with total revenue reaching $358 million, driven by $182 million in sales from the Sephience launch. The company raised its full-year 2026 revenue guidance to a range of $1.29 billion to $1.32 billion and expects to complete its BLA submission for the ST-920 Fabry disease gene therapy in Q4 2026.
“We delivered another strong quarter of record product revenue led by the continued momentum of the Sephience launch, putting us firmly on track to achieve our cash flow breakeven milestone this year. Now at the one-year mark, the launch has been a success by all measures. With a strong patient base, the large global market, and the reports of meaningful treatment benefits, we look forward to continued growth both in the US and internationally.”
PTC Therapeutics Director Michael Schmertzler Sells $149K of Stock
Michael Schmertzler, Director, sold 2,500 shares of PTC Therapeutics, Inc. at $59.52 to $60.14 a share (average $59.61) in 2 transactions, worth $149K in total on Oct 14, 2026. Shares held after the trade: 1,291,594 (-0.0%).
PTC Therapeutics Exec. VP and CLO Mark Elliott Boulding Sells $12.3K of Stock
Mark Elliott Boulding, Exec. VP and CLO, sold 192 shares of PTC Therapeutics, Inc. at $64.26 a share, worth $12.3K in total on Oct 9, 2026. Shares held after the trade: 105,272 (-0.2%).
PTC Therapeutics Director Michael Schmertzler Sells $155K of Stock
Michael Schmertzler, Director, sold 2,447 shares of PTC Therapeutics, Inc. at $63.38 a share, worth $155K in total on Oct 7, 2026. Shares held after the trade: 1,294,147 (-0.2%).
PTC Therapeutics Exec. VP and CLO Mark Elliott Boulding Sells $133K of Stock
Mark Elliott Boulding, Exec. VP and CLO, sold 2,073 shares of PTC Therapeutics, Inc. at $64.03 to $64.16 a share (average $64.06) in 2 transactions, worth $133K in total between Oct 5, 2026 and Oct 6, 2026. Shares held after the trade: 105,272 (-0.4%).
PTC Therapeutics Director Glenn Steele Jr. Md. Phd. Sells $782K of Stock
Glenn Steele Jr. Md. Phd., Director, sold 12,000 shares of PTC Therapeutics, Inc. at $65.16 a share, worth $782K in total on Sep 30, 2026. Shares held after the trade: 22,500 (-34.8%).
PTC Therapeutics M&A Deal with Sangamo Therapeutics, Inc.
PTC Therapeutics has completed its acquisition of ST-920 (isaralgagene civaparvovec), a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Therapeutics. The company expects to complete a rolling Biologics License Application (BLA) submission to the FDA for accelerated approval in the fourth quarter of 2026. The acquisition adds a potential one-time treatment for Fabry disease to PTC's rare disorder pipeline.
PTC Therapeutics Director Michael Schmertzler Sells $1.35M of Stock
Michael Schmertzler, Director, sold 20,000 shares of PTC Therapeutics, Inc. at $66.58 to $68.45 a share (average $67.49) in 4 transactions, worth $1.35M in total between Sep 16, 2026 and Sep 17, 2026. Shares held after the trade: 1,296,594 (-0.0%).